MacroGenics

MGNX69

Penny Stock

$3.81arrow_drop_up1.19%$0.04

Penny Stock

MGNX69

$3.81

arrow_drop_up1.19%$0.04

Penny Stock

Performance History

Key Stats
Open	$3.75
Prev. Close	$3.77
EPS	-1.57
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$239.44M
PE Ratio	-

	LOW	HIGH
Day Range	3.62	3.87
52 Week Range	2.95	21.88

Ratios







EPS	-1.57

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About MacroGenics (MGNX)

MacroGenics Inc (MGNX) is a biotechnology company that focuses on the discovery, development, and commercialization of innovative antibody-based therapeutics for the treatment of cancer. The company's lead product candidate is margetuximab, a monoclonal antibody that targets HER2-expressing tumors, including breast, gastric, and gastroesophageal junction cancers. Margetuximab is currently being evaluated in a Phase 3 clinical trial for the treatment of HER2-positive metastatic breast cancer.

In addition to margetuximab, MacroGenics has a robust pipeline of product candidates that target other cancer types and immune-related disorders. These include flotetuzumab, an antibody that targets CD123 for the treatment of acute myeloid leukemia, and teplizumab, an anti-CD3 antibody for the treatment of type 1 diabetes. The company also has several preclinical programs focused on bispecific antibodies and other immune-modulating therapies.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Scott Koenig M.D., Ph.D.
Headquarters: Rockville
Employees: 357
Exchange: NASDAQ

Keep an eye on MacroGenics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is MacroGenics 's (MGNX) price per share?

The current price per share for MacroGenics (MGNX) is $3.81. The stock has seen a price change of $0.04 recently, indicating a 1.19% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for MacroGenics (MGNX)?

For MacroGenics (MGNX), the 52-week high is $21.88, which is 474.28% from the current price. The 52-week low is $2.95, the current price is 29.11% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is MacroGenics (MGNX) a growth stock?

MacroGenics (MGNX) has shown an average price growth of -3.55% over the past three years. It has received a score of 11 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying MacroGenics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is MacroGenics (MGNX) stock price performance year to date (YTD)?

As of the latest data, MacroGenics (MGNX) has a year-to-date price change of -62.57%. Over the past month, the stock has experienced a price change of -10.98%. Over the last three months, the change has been 14.07%. Over the past six months, the figure is -14.38%. Looking at a longer horizon, the five-year price change stands at -54.53%.

help

Is MacroGenics (MGNX) a profitable company?

MacroGenics (MGNX) has a net income of -$9.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 86% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 48.95% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $58.75M, although specific revenue growth data is currently not available. The gross profit is $50.53M. Operating income is noted at -$168.24M. Furthermore, the EBITDA is -$99.71M.

help

What is the market capitalization of MacroGenics (MGNX)?

MacroGenics (MGNX) has a market capitalization of $239.13M. The average daily trading volume is 3.79, indicating the stock's liquidity and investor engagement.

News

MACROGENICS

APELLIS PHARMACEUTICALS

TERADATA

MAPLEBEAR

INVESTIGATION

FEDERAL AND STATE LAWS

FALSE AND MISLEADING STATEMENTS

Oct 23, 2024

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight

MACROGENICS

VOBRA DUO

SECURITIES CLASS ACTION

CLINICAL TRIAL

Sep 24, 2024

Hagens Berman Alerts MacroGenics (MGNX) Investors to Today’s Lead Plaintiff Deadline in Securities Class Action

Hagens Berman Reminds MacroGenics (MGNX) Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of Sept. 24, 2024

MGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

MACROGENICS

MGNX

SECURITIES CLASS ACTION LAWSUIT

PROSTATE CANCER DRUG

Sep 16, 2024

MACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline